

**APPENDIX. THERAPEUTIC CLASSES**

Data Supplement for Kornfield et al. (10.1176/appi.ps.201200147)

<b>Stimulants</b>	<b>Atomoxetine</b>	<b>Adderall</b>	<b>Substitutes</b>
ADDERALL	STRATTERA	ADDERALL	CATAPRES
ADDERALL XR		ADDERALL XR	CATAPRES TTS
AMPHETAMINE SALTS			CLONIDINE HCL
AMPHETAMINE SALTS ER			CLONIDINE TTS
AMPHETAMINE SULF			CLONIDINE ER
CONCERTA			CLONIDINE/CHLORLTHL
CYLERT			GUANFACINE HCL
DAYTRANA			TENEX
DEXEDRINE			BUPROPION HCL
DEXTROAMPHETAMINE			BUPROPION HCL SR
DEXTROSTAT			BUPROPION HCL XL
FOCALIN			WELLBUTRIN XL
FOCALIN XR			WELLBUTRIN
METADATE CD			WELLBUTRIN SR
METADATE ER			WELLBUTRIN UNSP
METADATE UNSP			
METHYLIN - MKR			
METHYLIN - SE2			
METHYLIN - SGI			
METHYLIN ER			
METHYLPHENIDATE			
PROCENTRA			
PROVIGIL			
RITALIN			
RITALIN LA			
RITALIN-SR			
VYVANSE			

## ANALYSES STRATIFIED BY PRIMARY CARE PHYSICIANS AND SPECIALISTS.

PRIMARY CARE PHYSICIANS																				
	ALL STIMULANTS					ADDERALL					NON-ADDERALL STIMULANTS					ATOMOXETINE				
	Dif. in market share*	Average Market Share	Slope	Change in Slope	Pred. share at end of period	Dif. in market share**	Average Market Share	Slope	Change in Slope	Pred. share at end of period	Dif. in market share*	Average Market Share	Slope	Change in Slope	Pred. share at end of period	Dif. in market share**	Average Market Share	Slope	Change in Slope	Pred. share at end of period
Pre advisory period JAN 04 – JAN 05	—	79.82 %	.21%/month	—	81.21%	—	36.12 %	.24%/month	—	37.51 %	—	43.70 %	-.06%/month	—	43.24 %	—	21.10 %	-.21%/month	—	19.93 %
After Adderall PHA FEB 05 – AUG 05	+2.83%	84.86 %	-.02%/month	-.23%/month	84.19%	-4.76%	33.64 %	.20%/month	-.04%/month	34.18 %	+8.59 %	51.22 %	-.22%/month	-.16%/month	50.52 %	-5.40 %** (.02)	14.74 %	.32%/month	+.53%/month	16.26 %
After atomoxetine PHA SEPT 05 – JAN 07	+5.49%	91.19 %	.21%/month	+.23%/month	93.10%	+2.15%	34.52 %	-.25%/month	-.45%/month	32.53 %	+2.50 %	56.67 %	.49%/month	+.71%/month	60.57 %	-5.70 %** (.02)	9.84%	-.15%/month	-.48%/month	8.41 %
After all ADHD meds PHA FEB 07 – DEC 08	-2.66%	91.66 %	.10%/month	-.11%/month	92.83%	+2.99%	28.95 %	-.58%/month	-.33%/month	23.11 %	-5.61 %	62.72 %	.69%/month	+.20%/month	69.85 %	+1.18 %	8.64%	-.08%/month	+.07%/month	7.72 %
SPECIALISTS																				
	ALL STIMULANTS					ADDERALL					NON-ADDERALL STIMULANTS					ATOMOXETINE				
	Dif. in market share*	Average Market Share	Slope	Change in Slope	Pred. share at end of period	Dif. in market share**	Average Market Share	Slope	Change in Slope	Pred. share at end of period	Dif. in market share*	Average Market Share	Slope	Change in Slope	Pred. share at end of period	Dif. in market share**	Average Market Share	Slope	Change in Slope	Pred. share at end of period
Pre advisory period JAN 04 – JAN 05	—	84.62%	-.21%/month	—	83.80 %	—	37.49%	-.30%/month	—	35.63 %	—	47.12%	.12%/month	—	47.93 %	—	16.05%	.73%/month	—	20.21 %
After Adderall PHA FEB 05 – AUG 05	+3.54%	86.56%	-.40%/month	-.19%/month	84.71 %	+14.22 %** (.02)	41.51%	2.67 %/month	-2.37%/month*	33.56 %	-9.67 %	45.05%	2.19%/month	+2.06%/month	51.50 %	-8.50 %** (.001)	11.32%	-.23%/month	-.96%/month	11.08 %
After atomoxetine PHA SEPT 05 – JAN 07	+1.40%	85.65%	-.01%/month	+.39%/month	85.51 %	8.89%	37.51%	-.26 %/month	+2.41%/month**	35.65 %	-8.69 %	48.14%	.38%/month	-1.80%/month	51.14 %	+2.37 %	12.26%	-.11%/month	+.12%/month	11.47 %
After all ADHD meds PHA FEB 07 – DEC 08	+1.40%	88.12%	.13%/month	+.14%/month	89.65 %	-3.40 %	24.94%	-.67 %/month	-.41%/month	17.95 %	+2.94 %	63.18%	.81%/month	+.42%/month	71.42 %	-1.07 %	9.40%	-.11%/month	+.00%/month	8.02 %

\*Difference between 1) the predicted market share at the beginning of the new time segment based on the regression for the prior time segment and 2) the predicted market share based on the regression for the new time segment.

\*\*Significant at the .05 level

Source: IMS Health National Disease and Therapeutic Index, 2004-2008